

## DAFTAR PUSTAKA

1. Toivanen R dan Shen MM. Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. *Development*. 2017 Apr 15;144(8):1382-1398.
2. Asril F, MYH E, Yunir PE. the Effect of Tamsulosin 0.4 Mg Administration Towards Alteration of Prostate Specific Antigen (Psa) Levels in Benign Prostatic Hyperplasia (Bph) Patients in Padang City. *Indones J Urol*. 2024;31(2):76–80.
3. World Health Organization. Global Cancer Observatory. 2020: 1-2.
4. World Health Organization. Global Cancer Observatory-Indonesia. 2020: 1-2.
5. Xu XF, Liu GX dan Guo YS. Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019. *Am J Mens Health*. 2021;15(4):15579883211036786.
6. Badan Penelitian dan Pengembangan Kesehatan Kementerian RI. Riset Kesehatan Dasar tahun. Jakarta. 2018
7. Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, et al. Comprehensive overview of prostatitis. *Biomed Pharmacother*. 2017 Oct;94:1064-1076.
8. Pirola GM, Verdacchi T, Rosadi S, Annino F, dan De Angelis M. Chronic Prostatitis: Current Treatment Options. *Res Rep Urol*. 2019 Jun 4(11):165-174
9. Zhang L, Wang Y, Qin Z, Gao X, Xing Q, et al. Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis. *J Cancer*. 2020 Jan 1;11(1):177-189.
10. David MK dan Leslie SW. Prostate Specific Antigen. StatPearls Publishing. 2022.
11. Dai X, Fang X, Ma Y dan Xianyu J. Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies. *Medicine (Baltimore)*. 2016;95(18):e3493.
12. Jue JS, Barboza MP, Prakash NS, Venkatramani V, Sinha V, et al. Re-examining prostate-specific antigen (PSA) density: defining the optimal

- psa range and patients for using psa density to predict prostate cancer using extended template biopsie. *Urology*. 2017;105:124–128
13. Mailana W, Dwi KP, Insani SWW dan Widayati P. Hubungan PSA, Free-PSA, dan Testosteron pada Pasien dengan Benign Prostate Hyperplasia (BPH) dan Kanker Prostat. *Pusat Sains dan Teknologi Akselerator-Batan*. 2015: 167-170.
  14. Piovesan AC, Freire Gde C, Torricelli FC, Cordeiro P, Yamada R, et al. Incidence of histological prostatitis and its correlation with PSA density. *Clinics (Sao Paulo)*. 2009;64(11):1049-51.
  15. Lee CH, Akin-Olugbade O dan Kirschenbaum. A. Overview of prostate anatomy, histology, and pathology. *Endocrinol Metab Clin North Am*. 2011 Sep;40(3):565-75,9-13.
  16. Ittmann M. *Anatomy and Histology of the Human and Murine Prostate*. Cold Spring Harb Perspect Med. 2018 May 1;8(5):a030346.
  17. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, et al. Benign prostatic hyperplasia. *Nat Rev Dis Primers*. 2016;2:16031.
  18. Ngai HY, Yuen KS, Ng CM, Cheng CH dan Chu SP. Metabolic syndrome and benign prostatic hyperplasia: An update. *Asian J Urol*. 2017 Jul;4(3):164-173.
  19. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E dan Parsons JK. The correlation between metabolic syndrome and prostatic diseases. *Eur Urol*. 2012 Mar;61(3):560-70.
  20. Parikesit D, Mochtar CA, Umbas R dan Hamid AR. The impact of obesity towards prostate diseases. *Prostate Int*. 2016;4(1):1-6.
  21. Fowke JH, Phillips S., Koyama T., Byerly S., Concepcion R., et al. Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. *BJU Int*. 2013;111:122–128.
  22. Parsons JK, Bergstrom J dan Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community dwelling men. *BJU Int*. 2008;101:313–318.
  23. Russo GI, Broggi G, Cocci A, Capogrosso P, Falcone M, et al. Relationship between Dietary Patterns with Benign Prostatic Hyperplasia

- and Erectile Dysfunction: A Collaborative Review. *Nutrients*. 2021;13(11):4148.
24. Bosch J.L., Bangma C.H., Groeneveld F.P dan Bohnen A.M. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. *Eur Urol*. 2008;53:819–827.
25. Patel ND dan Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. *Indian J Urol*. 2014;30(2):170-6.
26. Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. *Asian J Urol*. 2017;4(3):152-157.
27. Madersbacher S, Sampson N dan Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. *Gerontology*. 2019;65(5):458-464.
28. Ng M dan Baradhi KM. Benign Prostatic Hyperplasia. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2023.
29. Sebastianelli A, Russo GI dan Kaplan SA. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: comparison with placebo and tolterodine. *Int J Urol*. 2018;25:196–205.
30. Miernik A dan Gratzke C. Current Treatment for Benign Prostatic Hyperplasia. *Dtsch Arztebl Int*. 2020;117(49):843-854.
31. Allison SJ, Gibson W dan Mirabegron. Alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. *Ther Adv Urol*. 2018;10:411–419.
32. The National Institute for Health and Care Excellence (NICE), ed. London: 2015.
33. Pendegast HJ, Leslie SW dan Rosario DJ. Chronic Prostatitis and Chronic Pelvic Pain Syndrome in Men. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2024.
34. Kwan ACF dan Beahm NP. Fosfomycin for bacterial prostatitis: a review. *Int J Antimicrob Agents*. 2020 Oct;56(4):106106.

35. Magistro G, Wagenlehner FM, Grabe M, Weidner W, Stief CG, et al. Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. *Eur Urol.* 2016 Feb;69(2):286-97.
36. Rees J, Abrahams M, Doble A dan Cooper A. Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. *BJU Int.* 2015 Oct;116(4):509-25.
37. Murphy SF, Schaeffer AJ, Done J, Wong L, Bell-Cohn A, et al.. IL-17 Mediates Pelvic Pain in Experimental Autoimmune Prostatitis (EAP). *PLoS One.* 2015;10(5):e0125623.
38. Tran CN dan Shokes DA. Sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. *World J Urol.* 2013 Aug;31(4):741-6
39. Mehta P, Leslie SW dan Reddivari AKR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 12, 2023. Dysuria
40. McNaughton MC, MacDonald R dan Wilt TJ. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review, *Ann. Intern. Med.* 367–381.
41. Cho IR, Keener TS dan Nghiem HV. Prostate blood flow characteristics in the chronic prostatitis/pelvic pain syndrome, *J. Urol.* 2000; 133(5):1130–1133.
42. Roberts RO, Jacobson DJ dan Girman CJ. Low agreement between previous physician diagnosed prostatitis and national institutes of health chronic prostatitis symptom index pain measures, *J. Urol.* 2004; 171(1):279–283.
43. Coşkun A, Can U, Tarhan F, Kavukoğlu Ö, Narter KF. Reliability and validity of the National Institutes of Health Chronic Prostatitis Symptom Index questionnaire in the Turkish Population. *Turkish J Med Sci.* 2021;51(2):501–7.
44. Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. *BJU Int.* 2015 ;116(4):509–25.

45. Kogan MI, Ibishev KS, Naboka YL, Gudima IA, Ferzauli AK, et al. Antibiotic therapy of chronic bacterial prostatitis is more effective considering antibiotic susceptibility of all pathogens isolated. *Investig Clin Urol*. 2022 May;63(3):325-333.
46. Salisbury BH, Tadi P. 5-Alpha-Reductase Inhibitors. StatPearls Publishing. 2023.
47. Higazy A, Shorbagy AA, Shabayek M, Radwan A, Halim GN, Osman D, et al. Short course of dutasteride in treatment of a refractory category IIIB chronic prostatitis (A placebo-controlled study). *Prostate Int*. 2022 Dec;10(4):213-7
48. Higazy A, Shorbagy AA, Shabayek M, Radwan A, Halim GN, et al. Short course of dutasteride in treatment of a refractory category IIIB chronic prostatitis (A placebo-controlled study). *Prostate Int*. 2022 Dec;10(4):213-217.
49. Nachawati D, Patel JB. Alpha-Blockers. StatPearls Publishing. 2023.
50. Khattak AS, Raison N, Hawazie A, Khan A, Brunckhorst O, Ahmed K. Contemporary Management of Chronic Prostatitis. *Cureus*. 2021 Dec;13(12):e20243.
51. Perdana NR, Mochtar CA, Umbas R dan Hamid AR. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. *Acta Med Indones*. 2016;48(3):228-238.
52. Adjakly M, Ngollo M, Dagdemir A, Judes G, Pajon A, et al. Prostate cancer: The main risk and protective factors-Epigenetic modifications. *Ann Endocrinol (Paris)*. 2015;76(1):25-41.
53. Pettersson A, Kasperzyk JL, Kenfield SA, Richman EL, Chan JM, et al. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. *Cancer Epidemiol Biomarkers Prev*. 2012;21(3):428-36.
54. Downer MK, Kenfield SA, Stampfer MJ, Wilson KM, Dickerman BA, et al. Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study. *J Clin Oncol*. 2019;37(17):1499-1511.

55. Lin PH, Aronson W dan Freedland SJ. Nutrition, dietary interventions and prostate cancer: the latest evidence. *BMC Med.* 2015;13:3.
56. López-Plaza B, Bermejo LM, Santurino C, Caverro-Redondo I, Álvarez-Bueno C, Gómez-Candela C. Milk and Dairy Product Consumption and Prostate Cancer Risk and Mortality: An Overview of Systematic Reviews and Meta-analyses. *Adv Nutr.* 2019 May;10(suppl\_2):S212–23.
57. Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. *Cancer Epidemiol Biomarkers Prev.* 2014;23(8):1484-93.
58. Spence AR, Rousseau MC dan Parent MÉ. Sexual partners, sexually transmitted infections, and prostate cancer risk. *Cancer Epidemiol.* 2014;38(6):700-7.
59. Rider JR, Wilson KM, Sinnott JA, Kelly RS, Mucci LA, et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. *Eur Urol.* 2016;70(6):974-982.
60. Yang L, Xie S, Feng X, Chen Y, Zheng T, et al. Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysis. *Sci Rep.* 2015;5:14667.
61. Bhindi B, Wallis CJD, Nayan M, Farrell AM, Trost LW, et al. The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis. *JAMA Intern Med.* 2017;177(9):1273-1286.
62. Xu Y, Li L, Yang W, Zhang K, Ma K, et al. Association between vasectomy and risk of prostate cancer: a meta-analysis. *Prostate Cancer Prostatic Dis.* 2021;24(4):962-975.
63. Toivanen R dan Shen MM. Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. *Development.* 2017;144(8):1382–98.
64. Murray TBJ. *The Pathogenesis of Prostate Cancer.* Exon Publications. 2021.
65. Merriel SWD, Funston G dan Hamilton W. Prostate Cancer in Primary Care. *Adv Ther.* 2018;35(9):1285-1294.

66. Descotes JL. Diagnosis of prostate cancer. *Asian J Urol.* 2019;6(2):129-136.
67. Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. *BMJ.* 2018 Sep 5;362:k3519.
68. Streicher J, Meyerson BL, Karivedu V dan Sidana A. A review of optimal prostate biopsy: indications and techniques. *Ther Adv Urol.* 2019;11:1756287219870074.
69. Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, et al. Prostate cancer. *Nat Rev Dis Primers.* 2021;7(1):9.
70. Leslie SW, Soon-Sutton TL dan R I A. Prostate Cancer. StatPearls Publishing. 2023.
71. Kumar V, Abbas A dan Aster J. Robbins Basic Pathology. 10th ed. Elsevier. Philadelphia; 2017.
72. MD ECK. Chronic Prostatitis Histopathology, Male genital pathology. Available at: <https://webpath.med.utah.edu/MALEHTML/MALE099.html> (Accessed: 29 January 2024).
73. Kearns JT, Holt SK, Wright JL, Lin DW, Lange PH, et al. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. *Cancer.* 2018 Jul 1;124(13):2733-2739.
74. Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, et al. Prognostic biomarkers used for localised prostate cancer management: a systematic review. *Eur Urol Focus.* 2017;7:30065–30072.
75. Leslie SW, Chargui S dan Stormont G. Transurethral Resection of the Prostate. StatPearls Publishing; 2024.
76. Abdelmoteleb H, Rashed F dan Hawary A. Management of prostate abscess in the absence of guidelines. *Int Braz J Urol.* 2017 Sep-Oct;43(5):835-840.
77. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign

- Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment. *J Urol*. 2021 Oct;206(4):818-826.
78. Leslie SW, Chargui S dan Stormont G. Transurethral Resection of the Prostate. StatPearls Publishing. 2023.
79. Aboubakry S, Fadl TM, Moustapha A, Soufiane M, Eddine EAJ, Jamal EFM, et al. Pathological correlation between prostate biopsies and the radical prostatectomy, about 30 cases. *African J Urol*. 2021;27(1):1–4
80. Jo JK, Shinn SH, Kim KS dan Moon HS. Changes in Prevalence and Treatment Pattern of Benign Prostatic Hyperplasia in Korea. *Int Neurourol J*. 2021 Dec;25(4):347-3
81. Iskandar TN, Alvarino A, Linosefa L. Gambaran Pasien Benign Prostatic Hyperplasia Yang Dilakukan Transurethral Resection Of The Prostate Di Rsup Dr. M. Djamil Padang. *Jur Kes Andalas*. 2021
82. Yasifa FG, Sugiharto S. Gambaran histopatologi hasil Transurethral Resection of Prostate (TURP) pada pasien pembesaran prostat di RS Sumber Waras periode tahun 2014 – 2016. *Tarumanegara Medical Journal*. 2019; 1(3): 510-4.
83. Halimi R, Pratama AR. Outcome Comparison of Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia Patients in Karawang General Referral Hospital. *Ina J of Cancer*. 2019;13(3):69-74.
84. Yue L, Wang T, Ge Y, Ge M, Zhang C, et al. Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas. *Prostate*. 2019 Feb;79(3):312-319.
85. Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. StatPearls Publishing; 2024
86. Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. *Asian J Urol*. 2017 Jul;4(3):152-157.
87. Babinski MA, Manaia JH, Cardoso GP, Costa WS, Sampaio FJ. Significant decrease of extracellular matrix in prostatic urethra of patients with benign prostatic hyperplasia. *Histol Histopathol*. 2014 Jan;29(1):57-63.

88. Shetty P, Singh BMK, Shetty T, Bishnu A. Correlation of prostate specific antigen level with histopathological findings in patients with prostatic disease. *Trop J Path Micro* 2016;2(3):152-158.
89. Lesmana R. Prostatitis in Benign Prostatic Hyperplasia (BPH) patients in Sanglah general hospital, Denpasar. *Medicina (B Aires)*. 2018;49(1):14–6.
90. Faza GY, Sugiharto. Gambaran histopatologi hasil Transurethral Resection of Prostate (TURP) pada pasien pembesaran prostat di RS Sumber Waras periode tahun 2014-2016. *Tarumanagara Med J*. 2019;1(3):510–4.
91. Sarwar S, Adil MA, Nyamath P, Ishaq M. Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus. *Prostate Cancer*. 2017;2017:5687212.
92. Samad A, Fayyaz N, Siddiqa S, Akhter N, Saeed R, et al. Association of serum PSA levels with Histopathological Pattern of Prostate Lesions. *J Islamabad Med Dental Coll*. 2019; 8(2):92-95.
93. Krisna DM, Hariatmoko H, Pinzon RT. The accuracy of increased blood concentration of prostate-specific antigen to prostate malignancy. *Indonesian Journal of Medicine and Health*. 2018; 9(5):24-9.
94. Mwila PK, Essame P, Witts-Hewinson F, Yimbo M, Behnazir M. The histological prevalence of prostatitis at Potchefstroom Hospital: a cross-sectional study. *PAMJ*. 2024;47(8):1-8.
95. Das AG, Langade A. Does prostate specific antigen act as predictor in benign prostatic hyperplasia? An observational study. *International Journal of Health Sciences*. 2022;6(S2):1480-1488.
96. Pratiwi NET, Riastiti Y, Irawiraman H, Danial D. Hubungan Usia dan Kadar Prostate Specific Antigen (PSA) dengan Derajat Histopatologi Adenokarsinoma Prostat di RSUD Abdoel Wahab Sjahranie Samarinda. *J Kesehat Andalas*. 2023;12(2):64.

97. Ayyıldız SN, Ayyıldız A. PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer. *Turkish J Urol*. 2014 Jun;40(2):82–8.
98. Wulansari NS, Marindawati M. Profil Prostate Spesific Antigen (PSA) pada Penyakit Prostat di Rumah Sakit Umum Daerah Cengkareng Jakarta Barat. *Muhammadiyah J Geriatr*. 2020;1(1):18.
99. Ali A, Ozer G. How Should Prostate Specific Antigen Be Interpreted?. *Turkish Journal of Urology*. 2013;39(3): 188-93.
100. Kim DK, Kim SJ, Moon HS, Park SY, Kim YT, Choi HY, et al. The Role of TURP in Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy. *Korean Journal of Oncology*. 2010;51:313-317.
101. Thompson IM, Pauler DK, Goodman PJ, M.Tangen C, Lucia S, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level  $\leq$  4.0 ng per milliliter. *The New England journal of medicine*. 2004;350(22):2239-2246

